Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... -- The element of surprise has been a major advantage ... warning. Until now, epidemiologists had nothing to measure that ... in suboptimal responses to both the H1N1 pandemic of ... - http://photos.prnewswire.com/prnh/20141121/160242 That virus ... gene structural changes have been found that invariably to ...
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... The report, "Synthetic Biology Market by ... Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & ... Global Forecast to 2018", analyses and studies ... challenges. , Browse 99 market data tables ... and in-depth TOC of the global synthetic ...
(Date:11/21/2014)... November 21, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... ferrocyanide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3
... BHRT ) a company committed to delivering ... treat heart failure and,cardiovascular diseases, today announced financial ... Recent Clinical Highlights:, -- On July ... a preclinical,study involving the injection of myoblasts modified ...
... adaptive and assistive technology, MIDDLETOWN, NY and ... of the world,s first commercially available bionic hand,today ... 2008 da Vinci Award from the,National Multiple Sclerosis ... most innovative developments and,research in adaptive and assistive ...
... RICHMOND, Texas, July 30 DNA Heritage has recently,overcome ... severely,restricted the use of DNA testing and databases that ... through their DNA. The patent covers the,use of surnames ... Property Office (UK IPO) has now rendered a formal ...
Cached Biology Technology:Bioheart, Inc. Announces Financial Results for Second Quarter 2008 2Bioheart, Inc. Announces Financial Results for Second Quarter 2008 3Bioheart, Inc. Announces Financial Results for Second Quarter 2008 4Bioheart, Inc. Announces Financial Results for Second Quarter 2008 5Bioheart, Inc. Announces Financial Results for Second Quarter 2008 6Bioheart, Inc. Announces Financial Results for Second Quarter 2008 7Touch Bionics a 2008 da Vinci Award winner 2DNA Heritage Success in Patent Battle Helps Keep Genealogy DNA Test Prices Low 2
(Date:11/7/2014)... Calif. , Nov. 7, 2014  In conjunction with ... Police Departments, The Community Foundation of the Verdugos ... DNA JUSTICE PROJECT," a $250,000 initiative to keep ... initial phase. In its first six months of existence, the ... needed evidence support for local law enforcement. "Because ...
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... in the UTSA College of Sciences, is one ... receive a two-year $300,00 National Science Foundation (NSF) ... funding supports President Obama,s BRAIN Initiative, a federal ... that will demystify complex brain processes. , ... broken into the interactions of multiple components, each ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... been honored by the National Science Foundation with a ... with microfluidic devices, which promise to improve 3D tissue ... University of Texas College of Engineering in 2007, has ... tissue and cells on microchips. , Her devices produce ...
... The Federation of American Societies for Experimental Biology ... inaugural advocacy competition, Stand Up for Science. The competition ... the health, quality of life, or economy of local ... submitted by ,Stand With Science, a group of graduate ...
... the amphibians and reptiles of Sierra Madre Mountain Range, ... 100 species that contribute to the unique biodiversity of the region. ... more than 150 species. Out of these, a total of 49 ... a remarkable 32 endemic. In the world of reptiles, Luzon can ...
Cached Biology News:The amazing amphibians and reptiles of the Philippine island Luzon 2
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Macrophage-stimulating protein receptor...
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
...
Biology Products: